---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-299942"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:58:34.919273+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Taysha grants ~5.3M options and RSUs to top executives; adopts 4M-share inducement plan

## Summary
- CEO Sean Nolan receives 1,184,688 options and 1,184,688 RSUs (total ~2.37M shares).
- President & Head of R&D Sukumar Nagendran receives 863,617 options and 863,617 RSUs.
- CFO Kamran Alam receives 590,413 options and 590,413 RSUs.
- Options vest 25% at 1 year, then monthly over 3 years; RSUs vest equally over 4 years.
- Board adopted 2023 Inducement Plan reserving 4M shares for new-hire grants under Nasdaq Rule 5635(c)(4).

## SEC filing metadata
- accession: 0001193125-23-299942
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523299942/0001193125-23-299942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523299942/d574908d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-299942
- JSON: https://secwatch.observer/filing/0001193125-23-299942.json
- Plain text: https://secwatch.observer/filing/0001193125-23-299942.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.